기사

Prodizen, a medical device company specializing in cell therapy and regenerative medicine, announced that it has completed its lineup of four devices optimized for autologous blood and autologous cell treatment environments by introducing a new centrifuge, the ‘TD4B’.

Designed and managed for clinical applications by Prodizen, a domestic medical device company, the TD4B is a compact model that utilizes precision separation technology to support PRP (platelet-rich plasma) procedures. Equipped with digital control and RPM/RCF display functions, it is compatible with a variety of tube sizes, allowing for flexible adaptation to treatment kits used in hospitals.

With this launch, Prodigzen has added the TD4B to its existing GENICELL+, TD5C, and TD4C models, establishing a four-model PROSYS lineup, offering a choice of four devices tailored to the treatment environment and purpose. Each device is differentiated in functionality, capacity, and control method, making it ideal for a wide range of tissue regeneration treatments in fields such as orthopedics, rehabilitation medicine, and pain medicine.

In PRP treatment, the accuracy and stability of separating the highly concentrated platelet layer greatly affects the treatment outcome, so selecting equipment with precision and safety is an important criterion for achieving satisfactory results.

Especially in a market where non-medical devices and unapproved equipment are mixed together, the TD4B is an officially approved device that can be safely used in hospitals by completing international certifications such as CE, ISO, and KFDA, as well as import reports for cell centrifuges, thereby securing patients' trust and guaranteeing the safety of procedures.

A Prodizen official said, “The TD4B, developed by reflecting various practical feedback from medical sites, is a model that comprehensively features digital control, stable separation performance, and the ability to respond to various tubes.” He added, “In line with the expanding trend of autologous cell-based regenerative medicine treatments, we will provide a more precise and safe treatment environment through the PROSYS lineup.”

Founded in 1998, Prodizen was the first company in Korea to develop PRP tubes and fully introduce PRP procedures into the Korean medical field. It has since accumulated specialized technologies in cell therapy and blood application devices. Partnering with numerous orthopedic, rehabilitation, and pain medicine hospitals, Prodizen supplies medical devices and integrated solutions for PRP and BMC procedures. The company is also expanding the scope of cell therapy applications by securing approvals for new medical technologies in various fields, including ophthalmology and obstetrics and gynecology.

Currently, the company exports products to approximately 30 countries and is expanding its global network. Through continuous research and development, the company aims to become a global bio company that leads regenerative medicine solutions in the global market beyond Korea.

Medical Today Shin Chang-ho (ssangdae98@mdtoday.co.kr)